Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

US Previously Marketed

5

Possibly Marketed Outside US

3

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

DNA

5

Endothelial PAS domain-containing protein 1

5

Hypoxia-inducible factor 1 alpha

5

Trypanosoma

5

Phenylalanine-4-hydroxylase

3

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

3

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1919

5

2009

3

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Malaria

5

Prostate cancer

5

Arthritis

3

Diabetes mellitus

3

Gastric ulcer

3

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

8

Curative

5

Palliative

3

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Penetrant

5

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Ehrlich, P.

5

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

6

Mixture

2

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

8

FDA UNII

8

EPA CompTox

6

PUBCHEM

6

CHEBI

5

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

RESPIRATORY SYSTEM

2

DERMATOLOGICALS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

THROAT PREPARATIONS

2

ANTISEPTICS AND DISINFECTANTS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

THROAT PREPARATIONS

2

ANTISEPTICS AND DISINFECTANTS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Antiseptics

2

Acridine derivatives

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Salts, Hydrates, Esters, etc.

6

Principal Form

2

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 8 of 8 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

ESCULIN

1Y1L18LQAF

Export Data
Search for Structure

Status:

Possibly Marketed Outside US

First approved in 2009

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Phenylalanine-4-hydroxylase

interleukin-6 production

tumor necrosis factor production

Conditions:

Diabetes mellitus

Phenylketonuria, experimental

Esculin (Esculoside), a coumarin compound derived from the horse chestnut and the traditional Chinese herbs such as Cortex Fraxini, has long been used for treating inflammatory and vascular diseases. The main activities of Esculoside focus on capilla...

ry protection, as it improves capillary permeability and fragility. It is reported to inhibit catabolic enzymes such as hyaluronidase and collagenase, thus preserving the integrity of the perivascular connective tissue. Esculin has various biological activities including anti-oxidant activity, intestinal anti-inflammatory activity, anti-cancer activity and growth inhibition of human leukemia cells. Esculin inhibits lipid peroxidation and scavenges hydroxyl radicals in the rat liver and exerts anti-inflammatory activity in both carrageenan- and zymosan-induced paw edema in mice. Esculin has the gastroprotective effect in cold-restraint stress and pylorus ligation-induced ulcer models. Esculin is used in a microbiology laboratory to aid in the identification of bacterial species (especially Enterococci and Listeria).

ACRIFLAVINE

1T3A50395T

Status:

US Previously Marketed

First marketed in 1919

Class:

MIXTURE

Targets:

Hypoxia-inducible factor 1 alpha

Endothelial PAS domain-containing protein 1

Conditions:

Prostate cancer

Acriflavine (ACF) is a topical antiseptic. The hydrochloride form is more irritating than the neutral form. It is derived from acridine. Commercial preparations are often mixtures with proflavine. Acriflavine was developed in 1912 by Paul Ehrlich, a ...

German medical researcher, and was used during the First World War against sleeping sickness. ACF has known trypanocidal, antibacterial, and antiviral activities. Effects of ACF on cancer cells were first reported 50 years ago. By present time was demonstrated that ACF a drug, that binds directly to HIF-1 alpha and HIF-2 alpha and inhibits HIF-1 dimerization and transcriptional activity and thus has potent inhibitory effects on tumor growth and vascularization. Also Acriflavine in combination with 3,6-diaminoacridine (proflavine) could prove to be a potential antimalarial drug and its pharmacological action can be due to inhibition of gyrase activity. This is achieved through interaction of the ACF with the DNA substrate. This interaction may lead to conformation change in DNA unsuitable for binding of gyrase with DNA.

3,6-Diamino-10-methylacridinium

J276XBF77Z

Export Data
Search for Structure

Status:

US Previously Marketed

First marketed in 1919

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Hypoxia-inducible factor 1 alpha

Endothelial PAS domain-containing protein 1

Conditions:

Prostate cancer

Acriflavine (ACF) is a topical antiseptic. The hydrochloride form is more irritating than the neutral form. It is derived from acridine. Commercial preparations are often mixtures with proflavine. Acriflavine was developed in 1912 by Paul Ehrlich, a ...

German medical researcher, and was used during the First World War against sleeping sickness. ACF has known trypanocidal, antibacterial, and antiviral activities. Effects of ACF on cancer cells were first reported 50 years ago. By present time was demonstrated that ACF a drug, that binds directly to HIF-1 alpha and HIF-2 alpha and inhibits HIF-1 dimerization and transcriptional activity and thus has potent inhibitory effects on tumor growth and vascularization. Also Acriflavine in combination with 3,6-diaminoacridine (proflavine) could prove to be a potential antimalarial drug and its pharmacological action can be due to inhibition of gyrase activity. This is achieved through interaction of the ACF with the DNA substrate. This interaction may lead to conformation change in DNA unsuitable for binding of gyrase with DNA.

3,6-DIAMINO-10-METHYLACRIDINIUM CHLORIDE HYDROCHLORIDE

0596YAL51J

Export Data
Search for Structure

Status:

US Previously Marketed

First marketed in 1919

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Hypoxia-inducible factor 1 alpha

Endothelial PAS domain-containing protein 1

Conditions:

Prostate cancer

Acriflavine (ACF) is a topical antiseptic. The hydrochloride form is more irritating than the neutral form. It is derived from acridine. Commercial preparations are often mixtures with proflavine. Acriflavine was developed in 1912 by Paul Ehrlich, a ...

German medical researcher, and was used during the First World War against sleeping sickness. ACF has known trypanocidal, antibacterial, and antiviral activities. Effects of ACF on cancer cells were first reported 50 years ago. By present time was demonstrated that ACF a drug, that binds directly to HIF-1 alpha and HIF-2 alpha and inhibits HIF-1 dimerization and transcriptional activity and thus has potent inhibitory effects on tumor growth and vascularization. Also Acriflavine in combination with 3,6-diaminoacridine (proflavine) could prove to be a potential antimalarial drug and its pharmacological action can be due to inhibition of gyrase activity. This is achieved through interaction of the ACF with the DNA substrate. This interaction may lead to conformation change in DNA unsuitable for binding of gyrase with DNA.

3,6-DIAMINO-10-METHYLACRIDINIUM CHLORIDE

1TW3Q60E36

Export Data
Search for Structure

Status:

US Previously Marketed

First marketed in 1919

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Hypoxia-inducible factor 1 alpha

Endothelial PAS domain-containing protein 1

Conditions:

Prostate cancer

Acriflavine (ACF) is a topical antiseptic. The hydrochloride form is more irritating than the neutral form. It is derived from acridine. Commercial preparations are often mixtures with proflavine. Acriflavine was developed in 1912 by Paul Ehrlich, a ...

German medical researcher, and was used during the First World War against sleeping sickness. ACF has known trypanocidal, antibacterial, and antiviral activities. Effects of ACF on cancer cells were first reported 50 years ago. By present time was demonstrated that ACF a drug, that binds directly to HIF-1 alpha and HIF-2 alpha and inhibits HIF-1 dimerization and transcriptional activity and thus has potent inhibitory effects on tumor growth and vascularization. Also Acriflavine in combination with 3,6-diaminoacridine (proflavine) could prove to be a potential antimalarial drug and its pharmacological action can be due to inhibition of gyrase activity. This is achieved through interaction of the ACF with the DNA substrate. This interaction may lead to conformation change in DNA unsuitable for binding of gyrase with DNA.

ESCULIN SESQUIHYDRATE

QP6AL93RDW

Export Data
Search for Structure

Status:

Possibly Marketed Outside US

First approved in 2009

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Phenylalanine-4-hydroxylase

interleukin-6 production

tumor necrosis factor production

Conditions:

Diabetes mellitus

Phenylketonuria, experimental

Esculin (Esculoside), a coumarin compound derived from the horse chestnut and the traditional Chinese herbs such as Cortex Fraxini, has long been used for treating inflammatory and vascular diseases. The main activities of Esculoside focus on capilla...

ry protection, as it improves capillary permeability and fragility. It is reported to inhibit catabolic enzymes such as hyaluronidase and collagenase, thus preserving the integrity of the perivascular connective tissue. Esculin has various biological activities including anti-oxidant activity, intestinal anti-inflammatory activity, anti-cancer activity and growth inhibition of human leukemia cells. Esculin inhibits lipid peroxidation and scavenges hydroxyl radicals in the rat liver and exerts anti-inflammatory activity in both carrageenan- and zymosan-induced paw edema in mice. Esculin has the gastroprotective effect in cold-restraint stress and pylorus ligation-induced ulcer models. Esculin is used in a microbiology laboratory to aid in the identification of bacterial species (especially Enterococci and Listeria).

ESCULIN SODIUM

951F046A5J

Export Data
Search for Structure

Status:

Possibly Marketed Outside US

First approved in 2009

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Phenylalanine-4-hydroxylase

interleukin-6 production

tumor necrosis factor production

Conditions:

Diabetes mellitus

Phenylketonuria, experimental

Esculin (Esculoside), a coumarin compound derived from the horse chestnut and the traditional Chinese herbs such as Cortex Fraxini, has long been used for treating inflammatory and vascular diseases. The main activities of Esculoside focus on capilla...

ry protection, as it improves capillary permeability and fragility. It is reported to inhibit catabolic enzymes such as hyaluronidase and collagenase, thus preserving the integrity of the perivascular connective tissue. Esculin has various biological activities including anti-oxidant activity, intestinal anti-inflammatory activity, anti-cancer activity and growth inhibition of human leukemia cells. Esculin inhibits lipid peroxidation and scavenges hydroxyl radicals in the rat liver and exerts anti-inflammatory activity in both carrageenan- and zymosan-induced paw edema in mice. Esculin has the gastroprotective effect in cold-restraint stress and pylorus ligation-induced ulcer models. Esculin is used in a microbiology laboratory to aid in the identification of bacterial species (especially Enterococci and Listeria).

ACRIFLAVINE HYDROCHLORIDE

1S73VW819C

Status:

US Previously Marketed

First marketed in 1919

Class:

MIXTURE

Targets:

Hypoxia-inducible factor 1 alpha

Endothelial PAS domain-containing protein 1

Conditions:

Prostate cancer

Acriflavine (ACF) is a topical antiseptic. The hydrochloride form is more irritating than the neutral form. It is derived from acridine. Commercial preparations are often mixtures with proflavine. Acriflavine was developed in 1912 by Paul Ehrlich, a ...

German medical researcher, and was used during the First World War against sleeping sickness. ACF has known trypanocidal, antibacterial, and antiviral activities. Effects of ACF on cancer cells were first reported 50 years ago. By present time was demonstrated that ACF a drug, that binds directly to HIF-1 alpha and HIF-2 alpha and inhibits HIF-1 dimerization and transcriptional activity and thus has potent inhibitory effects on tumor growth and vascularization. Also Acriflavine in combination with 3,6-diaminoacridine (proflavine) could prove to be a potential antimalarial drug and its pharmacological action can be due to inhibition of gyrase activity. This is achieved through interaction of the ACF with the DNA substrate. This interaction may lead to conformation change in DNA unsuitable for binding of gyrase with DNA.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1